Singapur - angličtina - HSA (Health Sciences Authority)

astellas pharma singapore pte. ltd. - tacrolimus monohydrate 1.02 mg eqv anhydrous tacrolimus 1.0 mg - capsule, extended release - 1.0 mg - tacrolimus monohydrate 1.02 mg eqv anhydrous tacrolimus 1.0 mg 1.0 mg

Singapur - angličtina - HSA (Health Sciences Authority)

astellas pharma singapore pte. ltd. - tacrolimus monohydrate 5.1 mg eqv anhydrous tacrolimus 5.0 mg - capsule, extended release - 5.0 mg - tacrolimus monohydrate 5.1 mg eqv anhydrous tacrolimus 5.0 mg 5.0 mg

Spojené štáty - angličtina - NLM (National Library of Medicine)

watson laboratories, inc. - tacrolimus (unii: wm0haq4wnm) (tacrolimus anhydrous - unii:y5l2157c4j) - tacrolimus anhydrous 5 mg

Spojené štáty - angličtina - NLM (National Library of Medicine)

trupharma, llc - paroxetine hydrochloride anhydrous (unii: 3i3t11ud2s) (paroxetine - unii:41vrh5220h) - paroxetine 10 mg - major depressive disorder: paroxetine tablets are indicated for the treatment of major depressive disorder. the efficacy of paroxetine tablets in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology: clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine tablets in hospitalized depressed patients have not been adequately studied.

Spojené štáty - angličtina - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - paroxetine hydrochloride anhydrous (unii: 3i3t11ud2s) (paroxetine - unii:41vrh5220h) - paroxetine 20 mg - major depressive disorder: paroxetine tablets are indicated for the treatment of major depressive disorder. the efficacy of paroxetine tablets in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology: clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine tablets in hospitalized depressed patients have not been adequately studied.

Spojené štáty - angličtina - NLM (National Library of Medicine)

cardinal health - paroxetine hydrochloride anhydrous (unii: 3i3t11ud2s) (paroxetine - unii:41vrh5220h) - paroxetine 10 mg

Spojené štáty - angličtina - NLM (National Library of Medicine)

avera mckennan hospital - indinavir sulfate (unii: 771h53976q) (indinavir anhydrous - unii:9mg78x43zt) - indinavir anhydrous 400 mg

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nifedipine, quantity: 60 mg - tablet, modified release - excipient ingredients: iron oxide red; titanium dioxide; hypromellose; magnesium stearate; povidone; purified talc; macrogol 4000; carbomer 934p; lactose monohydrate; colloidal anhydrous silica; basic butylated methacrylate copolymer - treatment of hypertension. prophylaxis of chronic stable angina pectoris.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nifedipine, quantity: 30 mg - tablet, modified release - excipient ingredients: carbomer 934p; titanium dioxide; povidone; purified talc; iron oxide red; macrogol 4000; hypromellose; magnesium stearate; colloidal anhydrous silica; lactose monohydrate; basic butylated methacrylate copolymer - treatment of hypertension. prophylaxis of chronic stable angina pectoris.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nifedipine, quantity: 30 mg - tablet, modified release - excipient ingredients: hypromellose; povidone; colloidal anhydrous silica; titanium dioxide; iron oxide red; macrogol 4000; lactose monohydrate; magnesium stearate; purified talc; carbomer 934p; basic butylated methacrylate copolymer - treatment of hypertension. prophylaxis of chronic stable angina pectoris.